Agreement between administrative data and the Resident Assessment Instrument Minimum Dataset (RAI-MDS) for medication use in long-term care facilities: a population-based study by Lix, Lisa M. et al.
Lix et al. BMC Geriatrics  (2015) 15:24 
DOI 10.1186/s12877-015-0023-2RESEARCH ARTICLE Open AccessAgreement between administrative data and the
Resident Assessment Instrument Minimum
Dataset (RAI-MDS) for medication use in long-term
care facilities: a population-based study
Lisa M Lix1,2,3*, Lin Yan1, David Blackburn2, Nianping Hu3, Verena Schneider-Lindner4, Yvonne Shevchuk2
and Gary F Teare2,3Abstract
Background: Prescription medication use, which is common among long-term care facility (LTCF) residents, is
routinely used to describe quality of care and predict health outcomes. Data sources that capture medication
information, which include surveys, medical charts, administrative health databases, and clinical assessment records,
may not collect concordant information, which can result in comparable prevalence and effect size estimates. The
purpose of this research was to estimate agreement between two population-based electronic data sources for
measuring use of several medication classes among LTCF residents: outpatient prescription drug administrative
data and the Resident Assessment Instrument Minimum Data Set (RAI-MDS) Version 2.0.
Methods: Prescription drug and RAI-MDS data from the province of Saskatchewan, Canada (population 1.1 million)
were linked for 2010/11 in this cross-sectional study. Agreement for anti-psychotic, anti-depressant, and anti-anxiety/
hypnotic medication classes was examined using prevalence estimates, Cohen’s κ, and positive and negative agreement.
Mixed-effects logistic regression models tested resident and facility characteristics associated with disagreement.
Results: The cohort was comprised of 8,866 LTCF residents. In the RAI-MDS data, prevalence of anti-psychotics was 35.7%,
while for anti-depressants it was 37.9% and for hypnotics it was 27.1%. Prevalence was similar in prescription drug data for
anti-psychotics and anti-depressants, but lower for hypnotics (18.0%). Cohen’s κ ranged from 0.39 to 0.85 and was highest
for the first two medication classes. Diagnosis of a mood disorder and facility affiliation was associated with disagreement
for hypnotics.
Conclusions: Agreement between prescription drug administrative data and RAI-MDS assessment data was influenced
by the type of medication class, as well as selected patient and facility characteristics. Researchers should carefully consider
the purpose of their study, whether it is to capture medication that are dispensed or medications that are currently used
by residents, when selecting a data source for research on LTCF populations.
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Accurate measures of prescription medication use are
important for understanding the health and healthcare
use of long-term care facility (LTCF) residents. A large
percentage of LTCF residents have complex healthcare
needs for which one or more medications may be* Correspondence: lisa.lix@umanitoba.ca
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prescribing in this vulnerable population [2]. Measures
of medication use in previous studies about the quality
of care and health outcomes of LTCF residents include
anti-psychotic use in the absence of a psychotic disorder
or related condition, anti-depressant therapy in residents
without depression, and repeated use of hypnotic medi-
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LTCF residents include surveys, medical charts, adminis-
trative health databases, and patient clinical assessment
records. Resident surveys are sensitive to self-report or
recall biases, while medical chart reviews are time- and
labour-intensive to conduct, particularly for multiple
facilities. Population-based sources, including adminis-
trative health databases and assessment data like the
Resident Assessment Instrument Minimum Data Set
(RAI-MDS) [4,5], are ideal for making cross-facility or
inter-jurisdictional comparisons [6]. However, these data
sources were not originally intended for developing
facility-specific or jurisdiction-wide quality of care indi-
cators or for studying health outcomes. Administrative
data were developed for health system management and
monitoring, while the RAI-MDS clinical assessment data
were developed to improve resident care. Administrative
data do not contain the rich clinical and functional
information that is available in clinical assessments, but
assessment data contains less information about disease
diagnoses, which are essential to characterize patient
risk, than administrative data. Thus, there are advantages
and disadvantages to both data sources. Accordingly, stud-
ies about the comparability of the data in administrative
and clinical assessment data, including data on medication
use, are important to aid decisions about which source to
use in studies about LTCF residents.
Given this context, the purpose of this study was to
estimate agreement between medication information
recorded in population-based RAI-MDS and prescrip-
tion drug administrative data. This agreement analysis
was conducted for three medication classes that are fre-
quently prescribed for LTCF residents: anti-psychotic,
anti-depressant, and anti-anxiety/hypnotic medications.
Methods
Data sources
Data for this study were from the province of Saskatchewan,
Canada, which has a population of approximately 1.1
million according to the 2011 Statistics Canada Census,
and which has a universal healthcare program and
therefore captures virtually all healthcare contacts for
the entire population. The province maintains compre-
hensive health care databases in electronic format and
these can be anonymously linked via a unique personal
health number [7].
RAI-MDS Version 2.0, prescription drug, and person
registry system records from the 2010/11 fiscal year (a
fiscal year extends from April 1 to March 31), the most
current year available at the time of the study, were used
to conduct the research. The RAI-MDS, originally devel-
oped in the US by the Centers for Medicare and Medicaid
Services, captures information about care and functioning
of LTCF residents. This information is collected by trainedassessors, usually nurses, who use interviews with the
person and family members, consultation with other
clinicians, and chart review, to complete a form. Forms
are required to be completed within 14 days of LTCF
admission, quarterly and annually thereafter, and when-
ever there is a major change in a resident’s health status.
The RAI-MDS also captures dates of LTCF admission and
discharge and some characteristics of the LTCF itself.
Saskatchewan was the first Canadian province to make
the RAI-MDS mandatory in all LTCFs; this requirement
was introduced in April 2001, although full implementa-
tion was not achieved until 2004.
The prescription drug database contains records of
outpatient drugs dispensed to provincial residents eligible
for insurance coverage. It does not capture inpatient
medications, medications for residents of a small number
of LTCFs with in-house pharmacies, and approximately
10% of the population who are covered by a federally
funded pharmacare program (e.g., military, federal po-
lice, federal prisoners, First Nations residents). Each
available record includes the date of dispensation and
national drug identification number (DIN). DINs are
linked to codes in the American Hospital Formulary
System (AHFS) Pharmacologic-Therapeutic Classifica-
tion System (www.ashp.org), which is used to group
drugs with similar pharmacologic, therapeutic, and/or
chemical characteristics.
The person registry system captures dates of health
insurance coverage, demographic information, and loca-
tion of residence. The accuracy and completeness of
Saskatchewan’s administrative health data for research
has been well documented [8-12] although not specific-
ally for LTCF populations. Ethics approval for database
access was received from the University of Saskatchewan
Biomedical Research Ethics Board. Data were accessed
and analyzed at the provincial Health Quality Council
in accordance with a standing data sharing agreement
between that organization and the Ministry of Health.
Study cohort
The study cohort inclusion criteria were: (a) resident in
a LTCF for at least 60 days, (b) at least one admission,
quarterly, or annual RAI-MDS assessment during the
residency period, and (c) at least one record for a pre-
scription drug during the residency period. The latter
criterion was used to ensure that the cohort included
individuals eligible to receive prescription drug benefits.
The assessment date of the first admission, quarterly,
or annual RAI-MDS assessment in 2010/11 was the
study index date. The observation period extended
30 days before and 30 days after the index date. LTCF
residents who did not have continuous health insurance
coverage and were not eligible for prescription drug ben-
efits during the study observation period were excluded.
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Medication information was extracted from both the RAI-
MDS and prescription drug databases. Socio-demographic
variables were defined using the person registry data.
Additional information on resident and facility charac-
teristics were obtained from the RAI-MDS data.
The RAI-MDS captures the number of days of medica-
tion use in the seven-day period prior to the assessment
reference date. The following medication classes are
included in Section O of the assessment form: anti-
psychotic, anti-depressant, anti-anxiety, hypnotic, and
diuretic. Based on previous research, anti-anxiety and
hypnotic medication classes were combined into a single
category because they often have a similar indication and
diuretics were excluded because they tend to have lower
prevalence [13]. In the prescription drug administrative
data, anti-psychotic, anti-depressant, and anti-anxiety/
hypnotic medications were identified using generic drug
names (see Additional file 1) and AHFS codes from the
provincial formulary (i.e., drugs covered by prescription
drug benefits). The prescription drug database was
searched for dispensations of the three medications in the
study observation window. We selected a 60-day observa-
tion window because the medications under investigation
are commonly dispensed in one-month quantities [14]. A
sensitivity analysis was conducted using a 28-day observa-
tion window (i.e., 14 days before and 14 days after the
index date).
LTCF residents were described on the socio-demographic
characteristics of age, sex, region of residence, and income
quintile. All measures were defined at the index date.
Urban or rural region of residence was assigned based
on the postal code contained in the person registry.
Urban residents were those living in one of the two
health regions in the province that contain major urban
centres, while rural residents were those individuals
living in the remaining 11 health regions. Income quintile
was an area-level measure assigned based on average
household income from the Statistics Canada Census.
Each individual’s postal code from the person registry was
assigned to a dissemination area (DA), the smallest geo-
graphic unit for which Census data are reported. The
entire Saskatchewan population was then divided into five
approximately equal groups according to the DA average
household income [15]. Preliminary analysis of the data
showed that for three quarters (i.e., 74.0%) of cohort
members, the index date corresponded to the initial
assessment; accordingly, the resident’s postal code would
correspond to the place of resident prior to admission.
Selected chronic diseases identified in the RAI-MDS
were also captured for each member of the study cohort,
including Alzheimer’s disease, dementia, mood disorders
(i.e., anxiety, depression, bipolar), and schizophrenia,
which are potential indications for the medicationsunder investigations. These conditions were defined at
the study index date using admission and annual assess-
ments, or the most recent admission or annual assessment
if the index date was the date of a quarterly assessment
because not all diagnoses (e.g., schizophrenia) were cap-
tured in quarterly assessments.
Facility characteristics captured in the RAI-MDS data in
Saskatchewan include the type of facility and its affiliation.
These characteristics were defined at the study index date.
LTCFs were classified as special care home or other; the
former are public facilities for which residence is deter-
mined based on need, while the latter are typically private
facilities. LTCF affiliation includes amalgamate, affiliate,
and contract. Health regions may operate facilities on
their own (amalgamate), or the facility may be operated by
an independent health care organisation (affiliate), or
through a contract for services with an independent
organization (contract).
Statistical analysis
The study cohort was described using frequencies, percent-
ages, means, and standard deviations (SDs). Crude preva-
lence estimates (percentages) were calculated for each type
of prescription medication. Cohen’s κ was used to estimate
agreement between the RAI-MDS and administrative data;
95% confidence intervals (CIs) were also computed. The
interpretation of κ adopted in this study was [16]: κ < 0.20
is poor agreement, 0.20 ≤ κ ≤ 0.39 is fair agreement,
0.40 ≤ κ ≤ 0.59 is moderate agreement, 0.60 ≤ κ ≤ 0.79 is
good agreement, and κ ≥ 0.80 is very good agreement.
Mixed-effects multiple logistic regression models were
fit separately to the data for each medication to test resi-
dent and facility variables associated with disagreement
between the two data sources [17]. All individuals who
were identified as medication users in one data source
but not in the other data source were included in the
disagreement category, while individuals who were either
identified as medication users or as medication non-users
in both data sources were included in the agreement
category. Two models were fit to the data: (a) null
model, which contained a random facility intercept only,
to account for clustering of patients within facilities, and
(b) full model which contained a random intercept as well
as resident and facility fixed-effect covariates. Facility type
was excluded because it was collinear with affiliation. The
intra-class correlation (ICC) was computed for the null
and full models [17] using a latent variable method
[18]. The Akaike Information Criterion (AIC) was used
to compare model fit between the null and full models
[19]. The c-statistic, which is equal to the area under
the receiver operating characteristic (ROC) curve for
dichotomous outcomes, was used to assess discriminative
performance [20]; it was estimated for the full model
when the clustering effect.
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ported as odds ratios (ORs), along with 95% CIs. Analyses
were conducted using SAS software, version 9.2 [21].Results
A total of 9,913 individuals were identified as residents
in a Saskatchewan LTCF for at least 60 days in 2010/11.
Of this number, 350 (3.5%) did not have an RAI-MDS
admission, annual, or quarterly assessment, 477 (4.8%)
residents did not meet health insurance coverage or pre-
scription drug benefit requirements and 220 residents
(2.2%) did not have at least one prescription drug record
during the observation period, leaving 8,866 LTCF resi-
dents in the study cohort.
The average age of the cohort members was 84.1 years
(SD = 11.4; median = 86.0) and they had resided in a
LTCF for an average of 912.0 days (SD = 1381.5; median
= 465). More than two-thirds of the cohort was female
(68.2%; Table 1). Fewer individuals were in the highest
(13.8%) than in the lowest (22.2%) income quintile. More
than half (51.4%) of the study cohort had a diagnosis of
Alzheimer’s disease or dementia.
A total of 163 facilities were identified in the data; the
majority were amalgamates and special care homes. The
average number of study cohort members in each LTCF
was 54.4 (SD = 53.5; median = 37.0).Table 1 Characteristics of long-term care facility residents
in the study cohort (N = 8,866)
Variable Frequency (%)
Age Group
<65 years 608 (6.9)
65 – 74 years 768 (8.7)
75 – 84 years 2452 (27.7)
85+ years 5038 (56.8)
Sex
Male 2819 (31.8)
Female 6047 (68.2)
Income Quintile
Q1 (Lowest) 1970 (22.2)
Q2 1850 (20.9)
Q3 2146 (24.2)
Q4 1622 (18.3)
Q5 (Highest) 1220 (13.8)
Missing Quintile 58 (0.7)
Residence Location
Rural 4348 (49.0)
Urban 4398 (49.6)
Missing Location 120 (1.4)Crude medication prevalence estimates were 35.7%,
37.9%, and 27.1% for anti-psychotic, anti-depressant, and
anti-anxiety/hypnotic medications, respectively, from the
RAI-MDS data. The corresponding estimates for the
prescription drug data were 35.8%, 39.6%, and 18.0%.
Figure 1 contains crude estimates by age group. Prevalence
was highest for anti-depressants in residents less than
65 years of age; the estimate was 47.5% in the RAI-MDS
data and 50.2% in the prescription drug data.
Overall estimates of Cohen’s κ indicated very good
agreement for anti-psychotic and anti-depressant medi-
cations, but only moderate agreement for anti-anxiety/
hypnotic medications (Table 2). Estimates were similar
for younger and older age groups except for anti-anxiety
medications, which had slightly higher agreement in
younger than older individuals. Estimates were also
similar for males and females, although agreement was
slightly higher for females than males on anti-depressant
medications. In terms of disagreement between the two
data sources, the highest frequency was for residents
with anti-anxiety/hypnotics identified in the RAI-MDS
data but not in the prescription drug data. For the other
two types of medications, there were similar percentages
of disagreement between the two data sources.
Given the lower levels of agreement for anti-anxiety/
hypnotic medications, we focused only on this medication
when modeling the factors associated with disagreement
(Table 3). The facility-level variance was significantly
different from zero in the null model (variance = 0.05;
standard deviation = 0.02), but not in the full model. At
the same time, the ICC remained constant at 0.01 for both
the null and full models, providing little evidence of a
clustering effect in the data. The AIC revealed that the
full model (9010.3) was a better fit to the data than the
null model (9172.9). Discriminative performance of the
full model was moderate (c-statistic = 0.55). The ORs for
disagreement between the prescription drug administra-
tive data and the RAI-MDS data (Table 3) revealed that
the odds of disagreement were higher for residents with
a mood disorder and for residents of amalgamate than
contract facilities.
The sensitivity analysis conducted using the 28-day
observation window, produced similar results. Specifically,
Cohen’s κ ranged from 0.34 for anti-anxiety/hypnotic
medications to 0.78 for anti-psychotic medications.
Discussion
Deterministic record linkage techniques were used to
compare LTCF resident medication information captured
in prescription drug administrative data and RAI-MDS
data for the entire LTCF population of a Canadian prov-
ince. Agreement ranged from moderate to very good for
three medication classes captured in RAI-MDS data, and
was lowest for anti-anxiety/hypnotic medications. For this
Figure 1 Prevalence of medication use by type of medication class and age group.
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and the regional affiliation of the facility were associated
with disagreement, although the discriminative perform-
ance of resident and facility characteristics was modest.
When compared to prescription drug administrative
data, which captures information on medication dispen-
sations, it appears that the RAI-MDS clinical assessment
data, which captures information on utilization of medica-
tions, contain comparable information for anti-psychotic
and anti-depressant medication classes [22]. The small
size of the ICC for all medications indicates that there was
little variation across facilities in the lack of capture of
medication class information in either data source. How-
ever, for anti-anxiety and hypnotic medication classes, it
appears that there may be some differences across facility
affiliations, with those being operated by health regions
having slightly higher odds of disagreement compared
with those contracted to provide services by the health
region. This finding suggests that requirements aroundTable 2 Cohen’s κ and frequency (%) of agreement and disag
medication class use
A
Cohen’s κ (95% Confidence Interval)
All ages 0
<65 years 0
65+ years 0
Males 0
Females 0
Frequency (%) of Agreement/Disagreement
Positive Agreement: In RAI-MDS and Prescription Drug Data 2
Negative Agreement: In neither RAI-MDS nor Prescription Drug Data 5
Disagreement: In RAI-MDS & Not in Prescription Drug Data 3
Disagreement: Not in RAI-MDS & in Prescription Drug Data 3
Total 8completion of the RAI-MDS assessment form may not be
the same for different types of facilities. Higher disagree-
ment for residents with mental health conditions may, in
part, arise because it is more time consuming to complete
the assessment form for residents with complex needs,
leading to a higher potential for error or incomplete
capture of medication class information.
The high rate of disagreement between the RAI-MDS
and prescription drug data for anti-anxiety and hypnotic
medication classes may have arisen for a number of
reasons that are not captured in the study variables. Not
all anti-anxiety or hypnotic medications may be covered
by provincial health benefits, although this number will
be small [7]. The RAI-MDS assessment form does not
contain generic names or DINs, therefore LTCF staff may
not be able to correctly identify anti-anxiety or hypnotic
medications. A patient prescription might not always be
filled through a community pharmacy for anti-anxiety or
hypnotic medication classes and therefore might not bereement of RAI-MDS and prescription drug data on
nti-Psychotic Anti-Depressant Anti-Anxiety or Hypnotic
.85 (0.83, 0.86) 0.83 (0.82, 0.85) 0.40 (0.38, 0.42)
.81 (0.77, 0.86) 0.84 (0.79, 0.88) 0.46 (0.39, 0.54)
.85 (0.84, 0.86) 0.83 (0.82, 0.85) 0.39 (0.37, 0.41)
.82 (0.80, 0.84) 0.79 (0.76, 0.81) 0.39 (0.35, 0.43)
.86 (0.84, 0.87) 0.85 (0.84, 0.87) 0.40 (0.38, 0.43)
851 (32.2) 3087 (34.8) 1054 (11.9)
385 (60.7) 5079 (57.3) 5925 (66.8)
11 (3.5) 273 (3.1) 1347 (15.2)
19 (3.6) 427 (4.8) 540 (6.1)
866 (100.0) 8866 (100.0) 8866 (100.0)
Table 3 Odds ratios (ORs) and 95% confidence intervals
(95% CIs) and model characteristics for disagreement
between RAI-MDS and prescription drug data
Variable OR (95% CI)
85+ years 0.90 (0.72, 1.12)
75 – 84 years 0.97 (0.77, 1.21)
65 – 74 years 0.94 (0.72, 1.22)
<65 years Reference
Males 0.94 (0.84, 1.06)
Females Reference
Alzheimer’s/dementia: present 0.94 (0.84, 1.04)
Alzheimer’s/dementia: absent Reference
Mood disorders: present 1.37 (1.23, 1.54)*
Mood disorders: absent Reference
Schizophrenia: present 1.23 (0.91, 1.65)
Schizophrenia: absent Reference
Income Quintile: Q1 (lowest) 0.95 (0.79, 1.15)
Income Quintile: Q2 1.03 (0.85, 1.24)
Income Quintile: Q3 1.08 (0.90, 1.29)
Income Quintile: Q4 1.04 (0.86, 1.26)
Income Quintile: Q5 (highest) Reference
Rural residence 0.93 (0.81, 1.07)
Urban residence Reference
Affiliate facility 1.22 (0.92, 1.62)
Amalgamate facility 1.33 (1.01, 1.77)*
Contract facility Reference
Clustering Effect & Model Discrimination Estimate
Facility-level variance 0.04 (0.02)
Intra-class correlation (ICC) 0.01
c-statistic 0.55
*Indicates an OR that is statistically significant at α = .05.
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tion stocks may be kept in-house in LTCFs if they are used
on an infrequent or intermittent basis. As well, for medica-
tions used on an infrequent basis, the observation window
may need to be substantially widened in order to achieve a
high estimate of agreement if consumption does not occur
shortly after dispensation. However, we found that moving
from a 28-day to 60-day window had almost no impact on
prevalence estimates for this type of medication.
There are a number of considerations when choosing
between prescription drug administrative data and RAI-
MDS data for measuring medication use in residents of
LTCFs. Databases that contain prescription drug dispen-
sation records do not capture individuals who are not
covered by prescription drug benefit programs; this may
represent substantial portions of the population in some
jurisdictions. In Canada for example, prescription drug
dispensations are not routinely captured in someprovincial electronic database, or they are captured only
for individuals 65+ years of age [23]. At the same time,
some jurisdictions may not mandate collection of RAI-
MDS data for all LTCF residents, which will result in
less than complete population coverage and affect accur-
acy and generalizability of prevalence estimates. While
administrative data capture all drugs prescribed on an
outpatient basis, inpatient medications are not typically
captured; residents of LTCFs affiliated with acute care
inpatient facilities may be missed. While only a small
number of medication classes are captured in Section O
of the RAI-MDS form, medications administered in the
last seven days are captured; this will include medica-
tions prescribed while in hospital for individuals who are
transferred from an acute care facility to a LTCF.
This study has some limitations. An external validation
of each data source was not conducted, although a chart
abstraction study or patient medication review would be
difficult to undertake given the large number of facilities
and patients that would have to be sampled to produce
generalizable results; as well such a study would be very
expensive to undertake. The discriminative performance
of the model covariates was moderate for all of the
medications, suggesting that other covariates should be
considered as predictors of disagreement. As well, there
may be unmeasured confounding in the model due to
the limited set of covariates available for consideration.
For example, facility characteristics such as number and
type of staff might be useful to consider, but are not
currently captured in electronic databases.
Conclusions
This study of agreement between medication classes
captured in prescription drug administrative data and
clinical assessment data from the RAI-MDS suggests that
the medication information contained in both data sources
is consistent for anti-psychotics and anti-depressants. For
anti-anxiety and hypnotic medication ascertainment, low
agreement between the two data sources was not associated
with resident socio-demographic characteristics and was
only weakly associated with resident disease diagnoses or
facility type. While we hypothesize that agreement may be
associated with the pattern or frequency of use in LTCF
residents, further research is required to draw conclusions
about these effects.
Research about the optimal source of data to measure
medication use in LTCF populations is important for a
number of reasons. Medication use is a risk factor for
adverse health outcomes such as hip fracture. Accordingly,
failure to include measures of medication use in prediction
models represents a potential source of bias due to un-
measured confounding that could lead to erroneous con-
clusions [24]. Accurate measurement of medication use is
also critical to minimize variations in prescribing practices.
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